Chiesi bets $160M on Gos­samer Bio’s make-or-break late-stage PAH drug

Last year
Deals

Gly­coMimet­ic­s' AML drug flunks Phase 3 tri­al, quash­ing fil­ing plans as stock sinks

Last year
R&D

As­traZeneca ex­pands stake in cell and gene ther­a­py part­ner Cel­lec­tis

Last year
Financing
Pharma

Ex­clu­sive: New York biotech de­buts with $16M to find new ways to make sol­id can­cer cell ther­a­pies

Last year
Financing
Startups

Pfiz­er hires Citi an­a­lyst Baum to over­see port­fo­lio strat­e­gy

Last year
People
Pharma

No­var­tis’ ra­dio­phar­ma gam­bit; Weight loss bat­tle plays out; Spark co-founder’s new start­up; Q1 earn­ings ...

Last year
Weekly

J&J show­cas­es more blad­der can­cer re­sults from 'pret­zel' drug-de­vice com­bo

Last year
R&D
Pharma

Sen­a­tors from both par­ties in­tro­duce menopause re­search bill

Last year
Pharma

Ab­b­Vie puts $161M in­to new R&D site in Ger­many, will add 300 jobs

Last year
R&D
Pharma

House to mark up bill tar­get­ing Chi­nese biotech and ge­nomics com­pa­nies

Last year
China
Pharma

FTC wants more in­for­ma­tion on No­vo-Catal­ent deal in an­titrust re­view

Last year
Deals
Manufacturing

CG On­col­o­gy touts in­ter­im Phase 3 blad­der can­cer da­ta, gears up to com­pete with Im­mu­ni­ty­Bio

Last year
R&D

Dig­i­tal health start­up Ro’s CEO talks GLP-1 drug pric­ing, short­ages and com­pound­ed shots

Last year
Pharma
Health Tech

Roy­al­ty Phar­ma's mile­stone pay­ment to Ar­row­head; Abeon­a's $75M of­fer­ing

Last year
News Briefing

AEON fails an­oth­er mi­graine tri­al, shares halve as com­pa­ny re­views op­tions

Last year
R&D

Bi­par­ti­san draft bill would pay hos­pi­tals more to com­bat drug short­ages

Last year
Pharma
Manufacturing

Lon­nel Coats an­nounces re­tire­ment from Lex­i­con; An­oth­er shake­up in Vir's C-suite

Last year
Peer Review

Am­gen touts new da­ta for obe­si­ty drug Mar­i­Tide, mov­ing rapid­ly in­to Phase 3 work

Last year
R&D

Phar­ma com­pa­nies soft­en tone on full IRA im­pact

Last year
Pharma

Block­buster can­cer drug Calquence hits pri­ma­ry end­point in tri­al for first-line man­tle cell lym­phoma

Last year
R&D
Pharma

ICER push­es back on FDA's po­ten­tial con­ver­sion of Sarep­ta's gene ther­a­py to full ap­proval

Last year
Pharma
Cell/Gene Tx

No­vo nabs over a third of di­a­betes mar­ket, a year ahead of sched­ule

Last year
Pharma

Emer­gent to shut fa­cil­i­ties and lay off work­ers as part of new CEO’s roadmap

Last year
Manufacturing

Mod­er­na sticks to long-term strat­e­gy in first-quar­ter up­date, ends pact with Metageno­mi

Last year
Pharma
First page Previous page 162163164165166167168 Next page Last page
A service from the Financial Times